• Mathilda Mandel, Michael Gurevich, Michael Mandelboim, Howard Amital, and Anat Achiron.
• Blood Bank, Sheba Medical Center, Tel Hashomer, Israel.
• Isr Med Assoc J. 2021 Jan 1; 23 (1): 7-10.

BackgroundDuring the coronavirus disease-2019 (COVID-19) pandemic outbreak our blood bank developed protocols to guarantee accurate blood components to COVID-19 patients.ObjectivesTo provide convalescent whole blood donor screening strategies for patients recovering from COVID-19.MethodsWe recruited COVID-19 recovering patients who met our defined inclusion criteria for whole blood donation. All blood units were screened for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) RNA by real time reverse transcription polymerase chain reaction (RT-PCR) and SARS-COV-2 immunoglobulin G (IgG) antibodies against the S1 domain.ResultsWe screened 180 blood units from patients recovering from COVID-19. All results were negative for SARS-CoV-2 RNA and 87.2% were positive for SARS-COV-2 IgG antibodies in the plasma.ConclusionsBlood component units from recovering COVID-19 patients are safe. Plasma units with positive IgG antibodies could serve as an efficient passive immunization for COVID-19 patients. Moreover, in the face of increased transfusion demand for treatment of anemia and coagulation dysfunction in critical ill COVID-19 patients, red blood cells units and random platelets units from convalescent donors can be safely transfused.

27 keywords...

hide…